AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
Rhea-AI Summary
AIM (NYSE: AIM) announced final approval of a Japanese patent covering Ampligen (rintatolimod) combined with checkpoint inhibitors for cancer treatment, with claims that include pancreatic cancer.
The patent was granted in September 2025 after a 6-month opposition period and expires December 20, 2039. AIM also holds related patents in the U.S. (expires August 9, 2039) and the Netherlands (expires December 19, 2039) and plans to pursue Japanese Orphan Drug Designation for Ampligen in pancreatic cancer. The company already holds U.S. and EU orphan designations.
Positive
- Japan patent granted for Ampligen plus checkpoint inhibitors, covering pancreatic cancer
- Patent expiry dates: Japan Dec 20, 2039; U.S. Aug 9, 2039; Netherlands Dec 19, 2039
- Existing orphan designations in the U.S. and EU for Ampligen in pancreatic cancer
Negative
- Limited patent term remaining—Japan patent expires Dec 20, 2039
- No market approval yet; commercialization and exclusivity depend on future regulatory approval
News Market Reaction – AIM
On the day this news was published, AIM gained 43.66%, reflecting a significant positive market reaction. Argus tracked a peak move of +128.2% during that session. Our momentum scanner triggered 73 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 87.7x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AIM fell 2.93% while close peers were mixed: TNFA -9.72%, BCLI -6.67%, HCWB +6.97%, NCNA -1.06%, PMCB -5.36%. Momentum scanner also showed CYCN -2.70% and NCNA +3.23%, reinforcing stock-specific rather than unified sector trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 06 | Rights offering closing | Neutral | +4.3% | Closed rights offering raising about $1.8M via Units of preferred stock and warrants. |
| Mar 04 | Rights offering results | Neutral | -1.3% | Announced preliminary $1.8M aggregate subscriptions in rights offering ahead of closing. |
| Mar 02 | Phase 3 planning deal | Positive | -14.9% | Signed agreement to design proposed Phase 3 Ampligen trial after positive Phase 2 DURIPANC signals. |
| Feb 27 | Rights offering terms update | Negative | -8.3% | Updated rights terms, lowering prices and increasing warrants, emphasizing potential dilution. |
| Feb 25 | Offering extension | Negative | -4.7% | Extended subscription period for ongoing rights offering under an effective Form S-1. |
Positive clinical or development updates have previously seen negative price reactions, while dilutive or funding-related news has often aligned with share price weakness.
Over the past month, AIM has focused on capital raising and pancreatic cancer development. Multiple rights-offering updates and prospectus filings around February–March 2026 highlighted ongoing dilution and balance sheet repair, with several announcements followed by share price declines. In contrast, a March 2, 2026 agreement to plan a Phase 3 Ampligen trial and positive Phase 2 DURIPANC signals saw a -14.89% reaction. Today’s Japan patent approval extends the Ampligen oncology IP story built across the U.S. and Europe.
Regulatory & Risk Context
AIM has an effective S-3/A shelf filed on 2025-06-27, authorizing issuance of up to $100 million in various securities. Recent usage via multiple 424B prospectuses shows the company actively tapping this capacity, implying ongoing potential for additional equity or debt issuance.
Market Pulse Summary
The stock surged +43.7% in the session following this news. A strong positive reaction aligns with the strategically important news: final approval of broad Japanese IP for Ampligen plus checkpoint inhibitors through 2039. Prior data show that even clearly positive clinical or development updates sometimes met selling pressure, so a large gain on this event would stand out. Investors would still need to weigh ongoing capital-raising activity under the $100 million shelf and recent rights offerings as potential overhangs.
Key Terms
checkpoint inhibitors medical
anti-PD-1 medical
anti-PD-L1 antibodies medical
orphan drug designation regulatory
market exclusivity regulatory
AI-generated analysis. Not financial advice.
AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer
OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The patent was granted in September 2025, but had to then pass a 6-month opposition period. Japan is one of the largest health markets in the world, with Japan and the United States expected to experience the greatest increase in global pancreatic cancer burden by 2030. The Japan patent expires December 20, 2039.
The allowed claims in Japan cover an agent for treating cancer consisting of Ampligen in combination with a checkpoint inhibitor. The claims are broad and encompass multiple cancer types – including pancreatic cancer. AIM also holds a U.S. patent (expires August 9, 2039) for methods involving the use of Ampligen as part of a combination oncology therapy when paired with an anti-PD-L1 antibody and a patent in the Netherlands (expires December 19, 2039) for the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors, such as Keytruda (pembrolizumab), Opdivo (nivolumab) and Imfinzi (durvalumab).
AIM CEO Thomas K. Equels stated: “AIM is committed to developing Ampligen for the treatment of late-stage pancreatic cancer, which is an extremely lethal and unmet global health problem. Securing this critical patent in a key global market is just the latest step in AIM’s robust development and commercialization strategy.”
AIM also intends to expand its intellectual property portfolio by pursuing orphan drug designation in Japan for Ampligen in the treatment of pancreatic cancer. The Company already holds Orphan Drug designations for pancreatic cancer in the United States and the European Union. While the details of the designations vary by region, the purpose is to incentivize the development of therapies for unmet health needs, by providing various benefits and market exclusivity after a drug receives market approval.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. No assurance can be given that intention to seek Orphan Drug Designation will result in the granting of that status, nor that the possession of Orphan Drug Designations or any patents means that a drug will receive market approval. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.
Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the Registration Statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
FAQ
What did AIM (NYSE: AIM) announce about the Japan patent on March 18, 2026?
How does the Japan patent expiry for AIM's Ampligen compare to its U.S. and Netherlands patents?
Will AIM seek regulatory incentives in Japan for Ampligen for pancreatic cancer?
Does the Japan patent specifically cover Ampligen with Keytruda, Opdivo, or Imfinzi?
What are the near-term commercial implications for AIM after the Japan patent approval?
